
    
      Blood samples including the plasma and PBMC (peripheral blood mononuclear cell) from
      immunotherapy-naive lung cancer patients will be analyzed by CGP panel (OrigiMed, Inc.) for
      multiple molecular biomarkers including mutations with sensitivity/resistance to targeted
      therapies, bTMB, HLA, etc. Treatment methods and outcomes will be followed-up to inspect the
      clinical benefit and safety with CGP-panel analysis.
    
  